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Alzheimer’s disease (AD) is the most common neurodegenerative disorder in elderly people, but there are still no
curative options. Senile plaques and neurofibrillary tangles are considered hallmarks of AD, but cerebrovascular
pathology is also common. In this review, we summarize findings on cardiovascular disease (CVD) and risk factors in
the etiology of AD. Firstly, we discuss the association of clinical CVD (such as stroke and heart disease) and AD.
Secondly, we summarize the relation between imaging makers of pre-clinical vascular disease and AD. Lastly, we
discuss the association of cardiovascular risk factors and AD. We discuss both established cardiovascular risk factors
and emerging putative risk factors, which exert their effect partly via CVD.
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Alzheimer’s disease (AD) is the most common subtype
of dementia, and has a large patient and societal burden.
AD has a complex and multifactorial etiology that in-
volves senile plaques and neurofibrillary tangles [1]. In-
creasingly, the role of cardiovascular disease (CVD) is
also being recognized as an important etiologic hallmark
of AD. Indeed, many studies have shown the importance
of vascular pathology in AD [2-7]. As CVDs have estab-
lished therapeutic options and the risk factors of CVD
are modifiable, focusing on the association between vas-
cular pathology and AD might provide pathways to pre-
vent or delay AD in elderly individuals [8,9]. In this
narrative review, we provide an overview of the current
knowledge on the relation between AD and clinical
CVDs, imaging markers of pre-clinical CVD, and estab-
lished and emerging cardiovascular risk factors (Table 1).
Review
Cardiovascular disease
CVDs, such as stroke, atrial fibrillation, coronary heart
disease (CHD), and heart failure are very common in el-
derly individuals and have regularly been linked to AD.* Correspondence: m.a.ikram@erasmusmc.nl
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article, unless otherwise stated.This association might be due to shared risk factors be-
tween CVDs and AD, but there might also be a direct
causal association as cardiac disease causes hypoperfu-
sion and microemboli, which have been implicated in
the etiology of AD [10,11]. In the following sections, we
discuss current evidence relating common CVDs with
risk of AD.
Stroke
Clinical stroke has often been associated with an in-
creased risk of subsequent dementia, but this is by de-
finition then termed ‘post-stroke dementia’ or ‘vascular
dementia’ [12]. Such terminology hampers thorough in-
vestigation of the role of clinical stroke in AD. Therefore,
important evidence implicating stroke in the etiology of
AD comes from studies investigating asymptomatic or
‘silent’ stroke, which are often lacunae. Numerous studies
have shown that lacunae strongly increase the risk of de-
mentia, including AD [13-15]. Moreover, white matter le-
sions, which also represent ischemic brain damage, are
also associated with cognitive impairment and AD [16,17].
These findings suggest that stroke is causally involved in
the etiology of dementia. Mechanisms underlying this as-
sociation include the following. Firstly, stroke causes loss
of neuronal tissue, which might enhance the degenerative
effect of neuronal tissue loss as a result of amyloid and tau
pathology [15]. Secondly, it has been suggested that cere-
brovascular disease directly influences amyloid pathologyCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 List of potential vascular factors implicated in Alzheimer’s disease
Cardiovascular disease Pre-clinical markers of cardiovascular disease Established cardiovascular risk factors Emerging risk factors
Stroke Intima media thickness Blood pressure, hypertension, and arterial
stiffness
Inflammation
Atrial fibrillation Carotid plaques Glucose metabolism and diabetes mellitus Chronic kidney disease
Coronary heart disease Atherosclerotic calcification Hypercholesterolemia Thyroid function
Heart failure Lacunae and white matter lesions Smoking
Cerebral microbleeds Obesity
Cerebral microinfarcts Non-adherence to the Mediterranean diet and
low levels of physical activity
Retinal vascular changes Homocysteine
Microstructural integrity and connectivity
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pering amyloid β clearance [3,18], although studies on
these pathways remain inconsistent [3,18-21].
Atrial fibrillation
Several studies have shown that individuals with atrial
fibrillation (AF) more often have AD and are at an in-
creased risk of AD [22-24]. Because AF causes embo-
lisms that could lead to stroke, the relation between AF
and AD might be explained by clinical or silent stroke
[10,25-27]. Accordingly, a meta-analysis showed that a
consistent relation between AF and a higher risk of de-
mentia was restricted to individuals with stroke [23].
However, another study found that stroke-free individ-
uals with AF performed worse on memory and learning
tasks, and had a reduced hippocampal volume [28]. Both
memory function and hippocampal volume are strongly
related to AD, which suggests there might be additional
pathways explaining the association between AF and AD
[29]. One hypothesis is that cerebral hypoperfusion in
AF causes damage to nerve cells, and thereby contrib-
utes to the etiology of AD [23,25-27]. Another hypoth-
esis is that AF directly influences AD neuropathology,
such as senile plaques and neurofibrillary tangles, but
evidence for this explanation remains scarce [30].
Coronary heart disease
CHD is the most common type of heart disease, and one
of the major causes of death worldwide [31]. CHD in-
cludes angina pectoris, myocardial infarction (MI), and
coronary revascularization procedures. The relation be-
tween CHD and AD remains difficult to disentangle be-
cause of strong competing risks of death; several studies
showed that CHD is related to cognitive impairment or
AD [32,33], whereas others found no association [34,35].
The Rotterdam Study showed that unrecognized MI was
associated with the risk of AD, whereas recognized MI
was not [36]. Explanations linking CHD with AD include
shared etiology, as atherosclerosis plays an important
role in both CHD and AD [26,27]. This hypothesis iscorroborated by findings from the Cardiovascular Health
Study, which showed that peripheral artery disease, an-
other manifestation of atherosclerosis, was also strongly
associated with an increased risk of AD [32]. Further-
more, CHD might relate to AD through diminished car-
diac function, hypoperfusion, and emboli [10,25-27].
Heart failure
Heart failure represents a condition in which the pump-
ing function of the heart is diminished and unable to
supply the body with sufficient blood flow. Heart failure
has been associated with cognitive impairment and AD
[37-39]. A Swedish study found that heart failure was
related to an increased risk of dementia, including AD
[37]. The same study also found that treatment with
anti-hypertensive drugs slightly reduced this risk. The
Framingham Offspring Study showed that even in indi-
viduals without clinical heart failure, lower cardiac func-
tion was related to lower brain volume, an important
hallmark for dementia [40]. The pathways explaining
the role of heart failure in the etiology of AD are similar
to those of AF; heart failure results in hypoperfusion of
the brain, which leads to hypoxia and damage to nerve
cells [3,4,25-27]. Additionally, heart failure increases the
risk of emboli and microvascular pathology, such as
white matter lesions and lacunae, which in turn are re-
lated to an increased risk of dementia [10,25-27].
Pre-clinical markers of cardiovascular disease
Cardiovascular pathology gradually accumulates over
years before manifesting as a clinical event. Similarly,
AD pathology also accumulates over decades before
clinical symptoms occur. Consequently, several studies
have sought to investigate how such pre-clinical path-
ology relates to cognitive decline and AD.
Pre-clinical markers of large vessel disease
Using various imaging techniques, it is possible to assess
markers of pre-clinical large vessel disease. Intima me-
dia thickness (IMT) and carotid plaque are measures of
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tained via ultrasonography. Both IMT and carotid plaque
are more prevalent in patients with dementia and AD than
in cognitively healthy individuals [41]. Moreover, both
measures are related to increased cognitive decline in
patients with AD [42]. Additionally, several population-
based studies have shown that individuals with the highest
IMT measures have an increased risk of incident demen-
tia, including AD [32,43,44]. Carotid plaque scores were
also associated with an increased risk of AD in one study,
but this association lacked statistical significance [44]. An-
other marker of pre-clinical large vessel disease is calcifi-
cation volume in the atherosclerotic plaque, which can be
assessed using computed tomography (CT). Although cal-
cification is only part of the plaque, it is a suitable measure
of the underlying plaque burden [45]. CT has the disad-
vantage of radiation exposure, but CT measures of athero-
sclerotic calcification are more observer-independent than
ultrasonography measures. Few studies have investigated
the relation between CT-derived atherosclerotic calcifica-
tion and dementia, but some studies found that larger cal-
cification volumes in the coronary arteries, aortic arch,
and carotid arteries relate to worse cognitive performance
[46,47]. Moreover, larger calcification volume was associ-
ated with smaller brain tissue volumes and worse micro-
structural integrity of the white matter, which are both
factors related to an increased risk of AD [46]. Mecha-
nisms linking carotid large vessel disease to AD include
sub-clinical cerebral small vessel disease (see below), hy-
poperfusion, or shared etiology [3,4,6].
Pre-clinical markers of cerebral small vessel disease
Abundant evidence shows that structural imaging mar-
kers of cerebral small vessel disease, such as lacunae and
white matter lesions, are related to cognitive impairment
or AD [15-17,48-50]. Additionally, brain atrophy, which is
an established marker of dementia and AD, is partly influ-
enced by CVD [48,51,52]. Cerebral microbleeds (CMBs)
are an emerging vascular marker with great promise for
AD research. Both amyloid β and vascular pathology are
related to the etiology of CMBs, and therefore a link be-
tween CMBs and incident AD seems plausible [53-55].
However, this association still needs to be confirmed in
longitudinal studies. In recent years, it has also become
possible to visualize cerebral microinfarcts using high-
field magnetic resonance imaging (MRI) scanners, such as
7 T scanners. The role of these microinfarcts in AD re-
mains unclear, but is expected to be the focus of research
in coming years [56,57]. Although it is possible to measure
markers of cerebral small vessel disease, direct visualiza-
tion of the small cerebral arterioles in vivo remains diffi-
cult. Retinal imaging provides an easy tool to visualize
retinal vessels that originate embryologically from the
same tissues as cerebral vessels. Thus retinal imagingprovides a possibility to study the small vessels of the
brain in vivo. Retinal vessel diameter has been associ-
ated with white matter lesions, infarcts, brain atrophy,
and an increased risk of vascular dementia [58-60]. Al-
though a recent case–control study also found a link be-
tween AD and retinal microvascular changes [61], there is
currently no evidence relating retinal vessels to an in-
creased risk of AD longitudinally.
Measures of brain connectivity
In recent years, development of newer imaging tech-
niques has allowed quantification of more subtle brain
pathology such as changes in brain connectivity. Diffu-
sion tensor imaging (DTI) assesses the microstructural
integrity of the white matter, and studies have suggested
that DTI markers reflect a very early stage of vascular
brain pathology. Consequently, several studies have
shown loss of microstructural integrity in early AD or
even in mild cognitive impairment (MCI) [62-64]. How-
ever, longitudinal studies relating DTI markers to in-
cident AD are still largely lacking. Another novel MRI
technique is resting-state functional MRI, which mea-
sures brain function by functional connectivity at rest.
Several studies have shown that functional connectivity
is altered in patients with MCI and AD [65-69], but
again, robust longitudinal data are still lacking. More-
over, the role of cardiovascular risk factors in functional
MRI remains unclear.
Cardiovascular risk factors
In addition to clinical CVDs (see above), risk factors of
CVD have also been implicated in AD. The causal path-
way of these risk factors might be associated with clin-
ical disease, but there is also evidence directly linking
cardiovascular risk factors with AD.
Blood pressure, hypertension, and arterial stiffness
Several studies have related hypertension to brain at-
rophy, white matter lesions, and neurofibrillary tangles
[70-72]. Therefore, an association between hypertension
and AD is conceivable. Nonetheless, this association is
complex and differs with age [73]. Several studies show
mid-life hypertension to be related to an increased risk
of AD [74-77], whereas other studies failed to find an as-
sociation between late-life hypertension and dementia.
In fact, some studies even suggest low blood pressure
might be related to AD [73]. These inconsistencies have
yet not been elucidated, but it is suggested that blood
pressure decreases in the years before clinical onset of
dementia because of reduced physical activity and low-
ered body weight. Further research is still necessary to
verify this hypothesis [27].
A measure closely related to blood pressure and hy-
pertension is arterial stiffness, which can be measured as
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The difficulty in investigating arterial stiffness lies in the
fact that it can be caused by hypertension as well as lea-
ding to hypertension [78,79]. Arterial stiffness results in
increased pulsatile pressure, causing damage to the mi-
crovascular system of the brain [80], which in turn cau-
ses cognitive decline [80]. Indeed, some studies found a
relation between higher pulse pressure or higher pulse
wave velocity and an increased prevalence and risk of
cognitive decline or AD [81-83]; however, others could
not demonstrate such an association [84,85].
Glucose metabolism and diabetes mellitus
Type 2 diabetes mellitus (T2DM) is a complex disorder,
in which insulin resistance leads to higher circulating
blood glucose levels, which in turn lead to microvascular
damage in various organs. In the brain, T2DM has been
associated with infarcts and atrophy [86,87]. Accord-
ingly, many studies have confirmed that the risk of de-
mentia and AD is higher in individuals with T2DM [88].
Furthermore, the risk of AD is also increased in indi-
viduals with borderline T2DM, that is, pre-diabetes [89].
Besides microvascular damage, other potential mecha-
nisms relating T2DM with AD are direct neurotoxicity
due to increased glucose and insulin levels. A higher cir-
culating blood glucose level is toxic to nerve cells, as it
causes protein glycation and oxidative stress [88]. Insulin
is involved in amyloid β clearance from the brain, and
higher levels of insulin could disrupt this metabolism,
leading to increased amyloid β burden [88].
Hypercholesterolemia
Given the role of cholesterol in the clearance of amyloid
β, hypercholesterolemia has been suggested as a risk fac-
tor for AD. Support for this hypothesis comes from a
recent imaging study showing higher cholesterol levels
to be related to higher amyloid β levels [90]. Similarly,
apolipoprotein E ε4-carrier status, one of the most im-
portant genetic risk factors of AD, is related to increased
cholesterol levels [91]. However, results of epidemio-
logical studies on the association between hypercholes-
terolemia and AD have been inconsistent. Some studies
found that hypercholesterolemia in mid-life was associ-
ated with an increased risk of AD, whereas in late life
there was no association [92]. An explanation is that a
high cholesterol level in mid-life is a risk factor of AD,
whereas lower cholesterol levels in late life probably re-
flect pre-clinical disease, as lifestyle and dietary habits
change in individuals with sub-clinical dementia.
Smoking
Various longitudinal studies have established smoking
as a risk factor for dementia and AD [93]. Both the
Rotterdam Study and the Honolulu-Asia Aging Studyfound that the risk of dementia in smokers was higher
than that in non-smokers [94,95]. Furthermore, the
Honolulu-Asia Aging Study found that number of pack-
years was related to amyloid burden in the brain in a
dose–response manner [95]. Smoking contributes to
atherosclerosis, and has been related to cerebral small ves-
sel disease [49,96]. Additionally, tobacco contains many
neurotoxins, which might cause direct neuronal dam-
age [97]. However, the exact mechanisms underlying the
relation between smoking and dementia require further
investigation.
Obesity
Similar to hypertension and increased cholesterol levels,
the association between obesity and risk of dementia
and AD changes with age [98-100]. Obesity in mid-life is
associated with an increased risk of dementia and AD,
whereas in older age a higher body weight seems to have a
protective effect [100,101]. Individuals with sub-clinical
dementia gradually lose body weight due to altered life-
style and lowered food intake, and thus low body weight
might also be an early symptom of dementia [98-100]. In
contrast, mid-life obesity increases the risk of many chro-
nic diseases, including vascular diseases, and could be re-
lated to an increased risk of dementia and AD via those
pathways [101].
Mediterranean diet and physical activity
The Mediterranean diet is characterized by a high intake
of vegetables, fruits, cereals, and unsaturated fatty acids,
a moderate intake of fish, poultry, eggs, red wine, and
dairy products, and a low intake of saturated fats and red,
processed meats [102]. Adherence to a Mediterranean diet
has shown to reduce vascular disease and vascular risk
factors, and to lower inflammation and oxidative stress
[103]. Two recent meta-analyses concluded that adher-
ence to a Mediterranean diet might reduce the risk of AD
[104,105]. However, the number of studies with long
follow-up is limited, and further research is necessary to
confirm the potential protective effect of the Mediterra-
nean diet on AD.
Besides dietary habits, another potential modifiable fac-
tor to reduce AD risk is physical activity [9,106]. Physical
activity is inversely associated with CVD and diabetes, and
could therefore also reduce the risk of AD [107,108]. Al-
ternatively, physical activity could have a direct protective
effect on the risk of dementia, as it improves cerebral
perfusion and increases neurogenesis [109,110]. Sev-
eral epidemiological studies have associated a higher level
of physical activity with a reduced risk of dementia or
cognitive decline [111-115]. However, most of these stu-
dies had relatively short follow-up, and studies with
long follow-up periods have yielded inconsistent re-
sults [115,116]. For both physical activity levels and
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sality explaining short-term associations needs to be
considered [117].
Homocysteine
Plasma homocysteine levels reflect folate and vitamin
B12 status, and are related to renal function. Increased
homocysteine levels are associated with vascular disease,
and might have an effect on amyloid β and tau phosphor-
ylation. Consequently, high plasma homocysteine levels
have been related to an increased risk of AD [118]. Im-
aging and autopsy studies showed that increased homo-
cysteine levels were associated with brain atrophy and
neurofibrillary tangles [119,120]. However, not all studies
concur with these results. A recent study found that
plasma homocysteine levels were not related to AD, after
adjusting for folate or vitamin B12 deficiency and renal
dysfunction [121]. Further studies are needed to unravel
this association.
Emerging risk factors
In addition to the classic vascular risk factors, there are
other emerging risk factors that have been implicated in
AD, partly by vascular mechanisms.
Inflammation
Various inflammatory markers have been related to an
increased risk of dementia, including AD [122-124]. As-
trocytes and microglia activate the neuronal immune
system in response to pathogens such as infection and
vascular pathology [125,126]. Several studies showed
that senile plaques in the brains of patients with AD and
of AD transgenic mice models were surrounded by an
increased number of activated microglia [127]. Amyloid
β also activates the neuronal immune system, and might
cause a chronic inflammatory reaction that has a toxic
effect on nerve cells [126]. Moreover, recent genetic stu-
dies have uncovered various genes for inflammation and
immune response that seem to be associated with AD
[128]. However, there have been no major population-
based cohort studies studying inflammation in AD, and
trials studying the effect of immunotherapy on AD have
not yet been successful [126]. Hence, further studies
are required to elucidate the exact role of inflamma-
tion in AD.
Chronic kidney disease
In recent years, various studies have focused on the asso-
ciation between chronic kidney disease (CKD) and cogni-
tive decline or AD. Most [129-133], but not all [134] of
these studies found that low kidney function was related
to an increased risk of dementia, AD, or cognitive decline.
These inconsistencies might be due to methodological dis-
crepancies: different measures of kidney function wereused, and there was a large variation across the study pop-
ulations examined [132]. Mechanisms linking CKD and
dementia include shared risk factors (such as hyperten-
sion, arterial stiffness, smoking, and obesity) and direct
consequences of CKD (such as chronic inflammation, he-
modynamic changes, anemia, and uremic toxins) [129].
However, these pathways are not well established, and
should be investigated further.
Thyroid function
Thyroid hormone is important for brain function, and
thyroid dysfunction is a potentially reversible cause of
cognitive impairment [135]. Thyroid hormone is involved
in amyloid precursor protein (APP) regulation. Animal
studies have shown that APP expression is increased in
hypothyroidism, which leads to higher amyloid β levels
[135]. In addition, thyroid dysfunction is associated with
CVD, and could therefore influence AD pathology indir-
ectly [135]. Lastly, thyroid hormone levels alter as a conse-
quence of AD pathology through reduction in thyrotropin
releasing hormone secretion [136]. Observational studies
have shown both hypothyroidism and hyperthyroidism to
be related to AD, but not all studies could establish an
association [136-140].
Conclusion
In conclusion, there is abundant and converging evi-
dence showing that CVDs and cardiovascular risk fac-
tors play an important role in the etiology of AD. While
for some of these factors the mechanisms linking to AD
are clear, for others the association with AD is more com-
plex and needs further research to be completely unra-
veled. Nevertheless, given that these vascular factors are
currently the only known modifiable risk factors for AD,
the possibility of intervening with these factors to prevent
or delay AD merits more dedicated research.
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